Katherine was first diagnosed with cancer at just 16 - now at 27 she is cancer-free and wants to 'give something back' to the ...

Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling ...

Factors contributing to the ramifications of this disease as it stands include the socio-economic: overweight and obesity ...

Oxford BioDynamics announced the publication of a multi-institutional clinical study on Wednesday, confirming the accuracy of its EpiSwitch Colorectal No-Stool Test (NST) in detecting colorectal ...

Argent BioPharma , a clinical-stage biopharmaceutical company brings hope to epilepsy patients. For thousands of patients with refractory epilepsy?commonly referred to as drug-resistant epilepsy?the ...

The post contains 50 new customer stories, which appear at the beginning of each section of customer lists. The post will be ...

Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy ofOxford BioDynamics' EpiSwitch blood-based Colorectal No-Stool Test (NST) High ...